Replies to post #52085 on $heff's $tation of $tocks & $olid DD

[Investor100]

RGEN:Repligen Launches New Products in OPUS™ Line of Pre-Packed Chromatography Columns

- Larger Columns Expand Utility of Unique Open Platform for Biologics Purification -

Repligen Corporation (NASDAQ:RGEN - News) today announced the launch of its new larger-scale OPUS™ brand chromatography columns used in the manufacture of biopharmaceuticals. The OPUS™ (Open Platform User Specified) line extension is being introduced in response to rising market demand for disposable technologies in biopharmaceutical manufacturing. Such technologies are revolutionizing biomanufacturing by enabling increased facility flexibility and operating efficiencies. The new OPUS™ chromatography columns are now commercially available to biopharmaceutical manufacturers and developers worldwide.

http://finance.yahoo.com/news/Repligen-Launches-New-bw-4025254504.html?x=0

Investor 100

[$heff]

RGEN..$4.49 Moving higher here on low volume again. This has not had its run since receiving priority approval for their drug. It will move higher on low volume each day.

Repligen announced that the FDA has accepted for filing and granted Priority Review to the co's new drug application for SecreFlo for the improved detection of pancreatic duct abnormalities in patients with pancreatitis (RGEN) 4.21 : Under the Prescription Drug User Fee Act (PDUFA), the FDA's goal for completing a Priority Review and delivering a decision on marketing approval is reduced to six months, compared to ten months for a Standard Review. The FDA has assigned a PDUFA goal date of June 21, 2012 to the SecreFlo NDA.